Abstract

Previous studies have demonstrated that the chimeric monoclonal antibody rituximab significantly reduces clinical and radiological disease activity in relapsing-remitting multiple sclerosis as early as 4 weeks after the first administration. The exact mechanisms leading to this rapid effect have not yet been clarified. The aim of this positron emission tomography study was to assess central nervous system penetration as a possible explanation, using zirconium-89-labelled rituximab. No evidence was found for cerebral penetration of [89Zr]rituximab.

LanguageEnglish
Pages543-545
JournalMultiple Sclerosis
Volume24
Issue number4
Early online date1 Apr 2017
DOIs
Publication statusPublished - Apr 2018

Cite this

@article{73e9c73212374a2eb18401a13eeea3fd,
title = "Cerebral rituximab uptake in multiple sclerosis: A 89Zr-immunoPET pilot study",
abstract = "Previous studies have demonstrated that the chimeric monoclonal antibody rituximab significantly reduces clinical and radiological disease activity in relapsing-remitting multiple sclerosis as early as 4 weeks after the first administration. The exact mechanisms leading to this rapid effect have not yet been clarified. The aim of this positron emission tomography study was to assess central nervous system penetration as a possible explanation, using zirconium-89-labelled rituximab. No evidence was found for cerebral penetration of [89Zr]rituximab.",
keywords = "Multiple sclerosis, rituximab, monoclonal antibodies, B-lymphocytes, positron emission tomography, magnetic resonance imaging",
author = "Hagens, {Marloes Hj} and Joep Killestein and Yaqub, {Maqsood M} and {van Dongen}, {Guus Ams} and Lammertsma, {Adriaan A} and Frederik Barkhof and {van Berckel}, {Bart Nm}",
year = "2018",
month = "4",
doi = "10.1177/1352458517704507",
language = "English",
volume = "24",
pages = "543--545",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Cerebral rituximab uptake in multiple sclerosis

T2 - Multiple Sclerosis

AU - Hagens, Marloes Hj

AU - Killestein, Joep

AU - Yaqub, Maqsood M

AU - van Dongen, Guus Ams

AU - Lammertsma, Adriaan A

AU - Barkhof, Frederik

AU - van Berckel, Bart Nm

PY - 2018/4

Y1 - 2018/4

N2 - Previous studies have demonstrated that the chimeric monoclonal antibody rituximab significantly reduces clinical and radiological disease activity in relapsing-remitting multiple sclerosis as early as 4 weeks after the first administration. The exact mechanisms leading to this rapid effect have not yet been clarified. The aim of this positron emission tomography study was to assess central nervous system penetration as a possible explanation, using zirconium-89-labelled rituximab. No evidence was found for cerebral penetration of [89Zr]rituximab.

AB - Previous studies have demonstrated that the chimeric monoclonal antibody rituximab significantly reduces clinical and radiological disease activity in relapsing-remitting multiple sclerosis as early as 4 weeks after the first administration. The exact mechanisms leading to this rapid effect have not yet been clarified. The aim of this positron emission tomography study was to assess central nervous system penetration as a possible explanation, using zirconium-89-labelled rituximab. No evidence was found for cerebral penetration of [89Zr]rituximab.

KW - Multiple sclerosis

KW - rituximab

KW - monoclonal antibodies

KW - B-lymphocytes

KW - positron emission tomography

KW - magnetic resonance imaging

U2 - 10.1177/1352458517704507

DO - 10.1177/1352458517704507

M3 - Article

VL - 24

SP - 543

EP - 545

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 4

ER -